Post Mortem Tissue Donation of Pediatric Tumor Tissues and Cells

Sponsor
Ann & Robert H Lurie Children's Hospital of Chicago (Other)
Overall Status
Recruiting
CT.gov ID
NCT05120518
Collaborator
(none)
150
1
120
1.2

Study Details

Study Description

Brief Summary

The objective of this study is to utilize all donated pediatric tumor tissues and cells obtained from autopsy to prospectively develop novel patient derived orthotopic xenograft (PDOX) mouse models as well as in vitro cell culture model systems for pediatric cancers, and also provide tissue samples to other researchers and organizations (eg, CBTN, DIPG Registry, COG).

Condition or Disease Intervention/Treatment Phase
  • Other: Collection of post mortem tissue donation

Detailed Description

The objective of this study is to utilize all donated pediatric tumor tissues and cells obtained from autopsy to prospectively develop novel patient derived orthotopic xenograft (PDOX) mouse models as well as in vitro cell culture model systems for pediatric cancers, and also provide tissue samples to other researchers and organizations (eg, CBTN, DIPG Registry, COG).

This model system will then be subjected to 1) comprehensive histopathological and molecular characterizations during serial in vivo sub-transplantations; 2) cryopreserved for long term preservation of tumorigenicity; and 3) used for future biological studies and preclinical drug testing.

Study Design

Study Type:
Observational
Anticipated Enrollment :
150 participants
Observational Model:
Cohort
Time Perspective:
Prospective
Official Title:
Post Mortem Tissue Donation of Pediatric Tumor Tissues and Cells
Actual Study Start Date :
Aug 14, 2019
Anticipated Primary Completion Date :
Aug 14, 2029
Anticipated Study Completion Date :
Aug 14, 2029

Arms and Interventions

Arm Intervention/Treatment
Pediatric patients with cancer and non-cancer tumor types

Pediatric patients with cancer and non-cancer tumor types (solid, liquid, neuro-oncology and stem cell)

Other: Collection of post mortem tissue donation
Collection of post mortem tissue from pediatric participants with cancer and non-cancer tumor types from whom post mortem tissue donation and autopsy consent is obtained.

Outcome Measures

Primary Outcome Measures

  1. Procurement of pediatric cancer and non-cancer tumor tissue during autopsy with signed consent [Up to 5 years from procurement]

    Procurement of pediatric cancer and non-cancer tumor tissue during autopsy with signed consent. Tissue will be collected through a research tissue collection autopsy of the original tumor and other sites that are appropriate. Samples of both tumor and normal cells will be collected in addition to body fluids such as cerebrospinal fluid (CSF), blood, bone marrow, and skin biopsies for genomic testing.

Eligibility Criteria

Criteria

Ages Eligible for Study:
N/A and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Pediatric patients with cancer and non-cancer tumor types (solid, liquid, neuro-oncology)

  • Signed consent for post mortem tissue donation and autopsy

Exclusion Criteria:
  • Signed consent for post mortem tissue donation and autopsy not obtained

Contacts and Locations

Locations

Site City State Country Postal Code
1 Ann & Robert H. Lurie Children's Hospital of Chicago Chicago Illinois United States 60611

Sponsors and Collaborators

  • Ann & Robert H Lurie Children's Hospital of Chicago

Investigators

  • Principal Investigator: Angela Waanders, MD, Ann & Robert H Lurie Children's Hospital of Chicago

Study Documents (Full-Text)

None provided.

More Information

Additional Information:

Publications

Responsible Party:
Angela Waanders, Principle Investigator, Ann & Robert H Lurie Children's Hospital of Chicago
ClinicalTrials.gov Identifier:
NCT05120518
Other Study ID Numbers:
  • 2019-2982
First Posted:
Nov 15, 2021
Last Update Posted:
Nov 15, 2021
Last Verified:
Nov 1, 2021
Individual Participant Data (IPD) Sharing Statement:
Yes
Plan to Share IPD:
Yes
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Nov 15, 2021